Regenxbio sees cash, cash equivalents, securities sufficient into 2026

Expects its balance in cash, cash equivalents and marketable securities of $380.5M as of March 31, 2024 to fund its operations into 2026. This cash runway guidance is based on the company’s current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under the ABBV-RGX-314 collaboration, including a potential, one-time $200.0M milestone for achievement of first patient dosed in the first pivotal trial for suprachoroidal delivery for treatment of DR, and the potential monetization of a priority review voucher that may be received for RGX-121.